Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to your Pharmacy & Therapeutics Committee. Subscribers also receive monthly 1-page summary monographs on the agents that are useful for agendas and pharmacy/nursing inservices. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent to you in print and are also available online. Monographs can be customized to meet the needs of your facility. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X.
Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The March 2008 monograph topics are nebivolol, 6% hydroxyethyl starch 130/0.4 in 0.9% normal saline, romiplostim, tocilizumab, and prasugrel. The DUE is on nebivolol.
New drug application submitted for investigational antibiotic doripenem [press release].Raritan, NJ: Johnson & Johnson; June 6, 2007. http://www.jnj.com/news/jnj_news/20070606_121447.htm. Accessed September 21, 2007.
3.
New drug application submitted for investigational antibiotic doripenem [press release].Raritan, NJ: Johnson & Johnson; December 15, 2006. http://www.jnj.com/news/jnj_news/20061215_103306.htm. Accessed September 21, 2007.
JonesR.N., HuynhH.K., BeidenbachD.J., FristcheT.R., SaderH.S.Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J Antimicrob Chemo.2004; 54(1): 144–154.
9.
MoutonJ.W., TouzwD.J., HorrevortsA.M., VinksA.A.Comparative pharmacokinetics of the carbapenems: clinical implications. Clin Pharmacokinet.2000; 39(3): 185–201.
10.
ZhanelG.G., WiebeR., DilayL.. Comparative review of the carbapenems. Drugs.2007; 67(7): 1027–1052.
11.
FritscheT.R., StilwellM.G., JonesR.N.Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003). Clin Microbiol Infect.2005; 11(12): 974–984.
12.
WexlerH.M., EngelA.E., GlassD., LiC.In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates. Antimicrob Agents Chemother.2005; 49(10): 4413–4417.
13.
ChenY., GarberE., ZhaoQ.. In vitro activity of doripenem (S-4661) against multidrug-resistant gram-negative bacilli isolated from patients with cystic fibrosis. Antimicrob Agents Chemother.2005; 49(6): 2510–2511.
14.
HuynhH.K., BeidenbachD.J., JonesR.N.Delayed resistance selection for doripenem when passaging Pseudomonas aeruginosa isolates with doripenem plus an aminoglycoside. Diagn Microbiol Infect Dis.2006; 55(3): 241–243.
15.
Van WartS., BhavnaniS.M., PhillipsL., WiklerM.A., AmbroseP.G.Population pharmacokinetics (PPK) of doripenem (DOR) [poster]. 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; October 20-November 2, 2004; Washington, DC. Poster A-18.
16.
FlorenL., WiklerM., KilfoilT., GeY.A phase I open-label controlled study to evaluate the safety, tolerability, and pharmacokinetics (PK) of doripenem (DOR) administered intravenously to subjects with renal impairment. 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; October 20-November 2, 2004; Washington, DC. Poster A-17.
17.
FlorenL., WiklerM., KilfoilT., GeY.A phase I, double-blind, placebo-controlled study to determine the safety, tolerability, and pharmacokinetics (PK) of prolonged-infusion regimens of doripenem (DOR) in healthy subjects [abstract]. 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy: October 20-November 2, 2004; Washington, DC. Abstract A-16.
18.
MalafaiaO., UmehO., JiangJ.Doripenem versus meropenem for the treatment of complicated intra-abdominal infections [poster]. 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2006; San Francisco, CA. Poster L-1564b.
19.
SolomkinJ.S., UmehO., JiangJ., KanigaK., FriedlandI.Doripenem vs. meropenem with an option for oral step-down therapy in the treatment of complicated intra-abdominal infections [abstract]. 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2007; Chicago, IL. Abstract L-487.
20.
Rea-NetoA., NeidermanM., ProkocimerP.. Efficacy and safety of intravenous doripenem vs. piperacillin/tazobactam in nosocomial pneumonia [abstract]. 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2007; Chicago, IL. Abstract L-731.
21.
ClavelM., ProkocimerP., LeeM.. Efficacy of doripenem versus imipenem in patients with ventilator-associated pneumonia and high disease severity. 45th Annual Infectious Disease Society of America Meeting; October 4-7, 2007; San Diego, CA. Abstract 1081.
22.
ChastreJ., WunderinkR., ProkocimerP., LeeM., KanigaK., FriedlandI.Efficacy and safety of doripenem vs. imipenem for ventilator-associated pneumonia [abstract]. 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2007; Chicago, IL. Abstract L-486.
23.
HoriuchiM., KimuraM., TokumuraM., HasebeN., AraiT., AbeK.Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with beta-lactam antibiotics. Toxicology.2006; 222(1-2): 114–124.
24.
NakajimaY., MizobuchiM., NakamuraM.. Mechanism of the drug interaction between valproic acid and carbapenem antibiotics in monkeys and rats. Drug Metab Dispos.2004; 32(12): 1383–1391.
